August 17, 2026 07:56 AM GMT argenx SE | North America ALKIVIA Delivers: FcRn Biology Wins, IMNM De-Risked, DM Still Very Much Alive ALKIVIA validates FcRn biology in myositis, de-risks a likely IMNM filing, and suggests DM efficacy is real but underpowered, preserving substantial upside. Key Takeaways FcRn Biology Wins: The ALKIVIA dataset is better than feared and should largely close the debate that emerged following argenx's June R&D day. The study met its primary endpoint in the combined IMNM and DM po ...